HDAC9 and neoplasm: We therefore concluded that inhibition of class I–specific HDAC using domatinostat controls tumor growth owing to enhanced anti-tumor immune responses, while mitigating the toxicities seen using pan-HDAC inhibition (Wong et al., 2014).